GlobeNewswire

2024-09-27 00:34

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria

In pre-clinical studies, MNV-201 demonstrated improved engraftment and bone marrow reconstitution potential of patient derived hematopoietic stem cells

In vitro data also demonstrated improved ability to differentiate to erythroid cells, supporting potential for improvement in biomarkers of anemia

HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial cell therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation of a Phase Ib dose exploration clinical trial of MNV-201 in patients with Low Risk Myelodysplastic Syndrome (MDS).

Anemia is a common and serious symptom in patients with low-risk myelodysplastic syndrome (LR-MDS), affecting almost 90% of cases and is often the primary characteristic of the disease. Anemia in MDS can have a negative impact on quality of life and may correlate with decreased progression-free survival and overall survival. 

“The FDA’s clearance of our IND marks an important achievement for Minovia, allowing us to clinically evaluate our allogeneic mitochondrial cell therapy approach and proceed with the Phase Ib clinical program for this first-in-class allogeneic mitochondrial therapy for low risk MDS patients,” said Natalie Yivgi Ohana, PhD, CEO of Minovia. “We are pleased to have safely dosed two MDS patients enrolled in an ongoing study under the Israeli Ministry of Health. We look forward to treating additional patients under this IND, as well as to learning about the potential of MAT to improve anemia in this patient population.”

The Phase Ib clinical trial is an open-label, dose exploration study to evaluate the safety and efficacy of MNV-201 in subjects with low risk MDS. This trial will continue our campaign to evaluate dose exploration and safety of single or repeat dosing of MNV-201. The trial will also enable assessment of efficacy in improving anemia and durability of response. The study is expected to enroll at least three patients each in the low, medium and high dose cohorts, and up to a total of 15 patients in total. For more information visit clinicaltrials.gov.

About MNV-201
MNV-201 is an autologous hematopoietic stem cell product enriched with allogeneic mitochondria. MNV-201 aims to restore mitochondrial function in low risk MDS patient hematopoietic stem cells, resulting in improved differentiation to erythroid lineage with the potential to improve anemia. Preclinical research suggests the potential for safe dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for MNV-201 therapy.

About Minovia Therapeutics
Minovia Therapeutics Ltd. is a clinical stage biotechnology company advancing mitochondrial cell therapies for primary-genetic and age-related mitochondrial diseases. Minovia's clinical stage product candidate, MNV-201, is composed of mobilized peripheral blood, autologous CD34+ cells enriched with allogeneic, cryopreserved placental derived mitochondria, produced by Minovia's proprietary Mitochondrial Augmentation Technology (MAT). The enrichment of hematopoietic stem cells with healthy and functional mitochondria aims to restore stem cells function of patients suffering mitochondrial dysfunction, caused both by mtDNA mutations or deletions in pediatric patients suffering from primary mitochondrial diseases, or in adults with age-related bone marrow failure disorders. MNV-201 is currently in clinical studies for pediatric patients with single-large scale mtDNA deletion syndromes (Pearson Syndrome and Kearn Sayre Syndrome) with four patients successfully dosed; and in Low Risk Myelodysplastic Syndrome. For more information, please visit www.minoviatx.com or follow the Company LinkedIn.

About Low Risk Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are a group of bone marrow failures that occur when the blood-forming cells in the bone marrow become abnormal leading to an abnormal differentiation and production of one or more blood cell types. Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias or progression to acute myeloid leukemia (AML). MDS is generally a disease that develops with aging; the median age at diagnosis of MDS is ~70 years.

Mitochondrial Dysfunction in MDS: Scientific literature shows a correlation between mitochondrial dysfunction and MDS progression. It is known that ineffective hematopoiesis in MDS results from increased susceptibility of clonal myeloid progenitors to apoptosis. This may be triggered by intrinsic factors, such as mitochondrial polarization due to iron retention in ringed sideroblasts. A subset of MDS patients present with sideroblastic anemia, a phenotype common in Pearson Syndrome patients and which implicates mitochondrial dysfunction of HSPCs as part of the pathology of MDS.

Contact Information: Natalie Yivgi Ohana, Co-Founder and CEO

Phone: +972-74-7039954

Email: info@minoviatx.com


Primary Logo

source: Minovia Therapeutics

【立即投票】今個農曆新年你會如何度過? ► 立即投票

上一篇新聞︰2024-09-27 14:00  Publication relating to transparency notifications

下一篇新聞︰2024-09-27 00:22  摇滚名人堂揭晓 2024 年入选仪式特别嘉宾阵容

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
5
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
6
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
7
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
8
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
9
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
10
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
11
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
16
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
17
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
18
港股 | 蕭猷華:恒指春節前目標21500點
19
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
20
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
21
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
22
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
23
習近平應約與特朗普通電話,特:冀盡快與習見面
24
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
25
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
26
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
27
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
28
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
29
加州山火造成超500億美元損失,大量房主未買保險
30
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老